^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | paxalisib (GDC-0084) (mTOR inhibitor, PI3K inhibitor, AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY
Published date:
07/06/2023
Excerpt:
Kazia Therapeutics Limited...is pleased to announce that its lead program, paxalisib, has been awarded Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy....
